CINECA IRIS Institutional Research Information System

TRUSOLINO, Livio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.357
AS - Asia 17.641
EU - Europa 14.713
SA - Sud America 1.283
Continente sconosciuto - Info sul continente non disponibili 1.009
OC - Oceania 363
AF - Africa 230
Totale 56.596
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.503
CN - Cina 8.321
IT - Italia 4.512
SG - Singapore 3.128
DE - Germania 1.727
GB - Regno Unito 1.701
JP - Giappone 1.426
FR - Francia 1.244
BR - Brasile 972
HK - Hong Kong 858
VN - Vietnam 852
FI - Finlandia 801
IE - Irlanda 707
KR - Corea 705
IN - India 701
ES - Italia 666
CA - Canada 584
SE - Svezia 578
NL - Olanda 488
AU - Australia 285
PL - Polonia 281
TW - Taiwan 281
UA - Ucraina 274
BE - Belgio 271
CH - Svizzera 269
TR - Turchia 257
AT - Austria 238
BD - Bangladesh 168
ID - Indonesia 157
RU - Federazione Russa 150
MX - Messico 146
IL - Israele 126
GR - Grecia 114
PT - Portogallo 112
TH - Thailandia 100
AR - Argentina 96
DK - Danimarca 90
CZ - Repubblica Ceca 88
NZ - Nuova Zelanda 76
RO - Romania 75
IR - Iran 73
IQ - Iraq 72
NO - Norvegia 65
PK - Pakistan 59
SA - Arabia Saudita 59
HU - Ungheria 49
ZA - Sudafrica 49
CL - Cile 48
MY - Malesia 47
CO - Colombia 46
EC - Ecuador 44
EG - Egitto 37
MA - Marocco 35
EE - Estonia 32
UZ - Uzbekistan 32
JO - Giordania 31
LT - Lituania 29
PE - Perù 26
JM - Giamaica 25
PH - Filippine 24
LB - Libano 20
TN - Tunisia 19
VE - Venezuela 19
AM - Armenia 18
HR - Croazia 18
KE - Kenya 18
NP - Nepal 18
SI - Slovenia 18
RS - Serbia 17
CR - Costa Rica 16
AE - Emirati Arabi Uniti 15
SK - Slovacchia (Repubblica Slovacca) 15
DZ - Algeria 14
MO - Macao, regione amministrativa speciale della Cina 14
SN - Senegal 14
TT - Trinidad e Tobago 14
UY - Uruguay 14
BG - Bulgaria 13
NG - Nigeria 13
LV - Lettonia 12
QA - Qatar 12
KZ - Kazakistan 11
NI - Nicaragua 11
BA - Bosnia-Erzegovina 10
LK - Sri Lanka 10
PR - Porto Rico 10
AL - Albania 9
BO - Bolivia 9
CY - Cipro 8
LU - Lussemburgo 8
PY - Paraguay 8
AP - ???statistics.table.value.countryCode.AP??? 7
BY - Bielorussia 7
EU - Europa 7
GT - Guatemala 7
HN - Honduras 7
PA - Panama 7
BH - Bahrain 6
GE - Georgia 6
OM - Oman 6
Totale 55.495
Salva come PNG Salva come JPEG
Città #
Singapore 1.812
Beijing 1.665
Ashburn 1.304
Chandler 1.119
Shanghai 1.114
Ann Arbor 1.052
Fairfield 843
San Jose 794
Houston 712
Dublin 655
Santa Clara 654
Milan 562
Redwood City 556
Guangzhou 539
Turin 493
Cambridge 485
Tokyo 485
Seattle 465
Woodbridge 410
Wilmington 407
Los Angeles 388
New York 388
Torino 380
Hong Kong 328
Helsinki 320
Nanjing 301
Munich 289
Hangzhou 258
Ho Chi Minh City 256
Dearborn 241
Boston 236
Rome 236
Dallas 225
Columbus 221
Seoul 218
The Dalles 215
Jacksonville 213
Nyköping 193
Villeurbanne 193
Wuhan 191
Chicago 190
London 188
Princeton 188
Hanoi 180
San Diego 177
Warsaw 175
Medford 171
Boardman 170
Pisa 162
Vienna 161
Lauterbourg 160
Lappeenranta 159
Naples 158
Paris 158
Hefei 152
Taipei 152
Chengdu 145
Barcelona 134
Buffalo 134
Amsterdam 129
São Paulo 126
Toronto 121
San Francisco 119
Zhengzhou 119
Jakarta 113
Council Bluffs 112
Fremont 111
Changsha 106
Madrid 106
Manchester 104
Frankfurt am Main 98
Tianjin 91
Atlanta 90
Phoenix 90
Bengaluru 88
Brussels 88
Duncan 87
Central 86
Genoa 85
Istanbul 85
Berlin 83
Ottawa 83
Jinan 79
Shenyang 79
Philadelphia 78
Shenzhen 77
Dong Ket 75
Chongqing 73
Sydney 73
Mumbai 72
Central District 70
Montreal 63
Nanchang 62
Nuremberg 62
Nashville 60
Bologna 59
Norwalk 58
Fuzhou 55
Osaka 53
Washington 53
Totale 28.051
Salva come PNG Salva come JPEG
Nome #
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. 7.414
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 6.281
Adaptive mutability of colorectal cancers in response to targeted therapies 2.634
Stromal contribution to the colorectal cancer transcriptome. 2.200
MET signalling: principles and functions in development, organ regeneration and cancer. 2.019
Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy 1.910
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.343
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 1.003
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 978
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 978
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 827
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 754
The genomic landscape of response to EGFR blockade in colorectal cancer 563
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 456
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 456
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 454
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer 435
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. 433
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 409
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 389
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 389
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype 367
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 346
Only a subset of Met-activated pathways are required to sustain oncogene addiction 342
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 338
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer 327
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 318
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 317
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis 314
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 314
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 311
Inhibition of Src impairs the growth of met-addicted gastric tumors. 306
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 305
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells 304
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 293
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 287
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 287
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors 265
Effective drug combinations in breast, colon and pancreatic cancer cells 259
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 258
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 256
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 251
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga 249
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 242
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils 239
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS. 237
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 234
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy 232
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells 231
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 224
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer 224
Inhibition of polyADP-ribosylation in cancer: Old and new paradigms revisited. 222
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 219
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 216
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 215
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 214
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 209
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 205
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. 203
PDX-MI: Minimal information for patient-derived tumor xenograft models 200
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis 196
CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system 191
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 191
The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle 188
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases 184
Differential integrin expression in thyroid and laryngeal carcinomas. 179
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. 178
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation 174
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin 172
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 172
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 171
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 161
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 159
TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer 157
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 156
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 156
Metabolic adaptation in colorectal cancer: heme export is required for the modulation of the tricarboxylic acid cycle. 155
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 152
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients 150
A monoclonal antibody identifies a novel GPI-anchored glycoprotein involved in epithelial intercellular adhesion. 150
Altered expression of alpha 6 integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions. 149
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer 148
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. 148
Animal research: Temper Italy's strict lab-animal law. 147
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways 147
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) 146
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle. 144
Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity 143
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models 143
Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma 142
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 140
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue 140
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 139
A membrane glycoprotein identified by the monoclonal antibody BD31 is a component of cell-cell junctions of normal and transformed epithelia. Eur J Cell Biol, 55 (Suppl 35): 54, 1991 139
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 138
Met as a potential therapeutic target in basal-like breast cancer 137
Interactions between scatter factors and their receptors: hints for therapeutic applications 136
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. 136
A novel GPI-anchored glycoprotein shows properties of a COOH-terminus truncated cadherin involved in cell-cell contacts of cultured human epithelial cells. 136
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells 134
Totale 48.929
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.652
article - articoli 0
book - libri 0
conference - conferenze 15.064
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 139.716
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.498 0 543 490 567 459 423 482 453 457 331 673 620
2022/20235.297 463 424 302 504 415 805 407 467 546 243 365 356
2023/20245.578 466 504 352 487 403 494 450 457 167 562 667 569
2024/20258.487 399 546 574 718 1.255 683 559 669 903 662 643 876
2025/202612.656 1.187 679 765 1.240 1.317 716 1.696 658 1.154 934 725 1.585
2026/20271.269 614 655 0 0 0 0 0 0 0 0 0 0
Totale 56.596